{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=47",
    "query": {
      "intervention": "Placebo- C",
      "page": 47
    },
    "page_size": 10
  },
  "pagination": {
    "page": 47,
    "page_size": 10,
    "total_count": 1835,
    "total_pages": 184,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=48&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=46&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T23:14:01.062Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00781482",
      "title": "Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "eszopiclone, zolpidem, placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kettering Health Network",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "MALE",
        "summary": "18 Years to 35 Years · Male only"
      },
      "enrollment_count": 0,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-02-26",
      "last_synced_at": "2026-10-29T23:14:01.062Z",
      "location_count": 1,
      "location_summary": "Kettering, Ohio",
      "locations": [
        {
          "city": "Kettering",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00781482"
    },
    {
      "nct_id": "NCT00231569",
      "title": "Dose-escalating Safety Study in Subjects on Stable Statin Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "ISIS 301012 or Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kastle Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 74,
      "start_date": "2005-09",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2016-08-03",
      "last_synced_at": "2026-10-29T23:14:01.062Z",
      "location_count": 1,
      "location_summary": "Auburn, Maine",
      "locations": [
        {
          "city": "Auburn",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00231569"
    },
    {
      "nct_id": "NCT06545097",
      "title": "A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Pain"
      ],
      "interventions": [
        {
          "name": "Cebranopadol 400 ug",
          "type": "DRUG"
        },
        {
          "name": "Cebranopadol 200 ug",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tris Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 279,
      "start_date": "2024-09-03",
      "completion_date": "2024-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-10-29T23:14:01.062Z",
      "location_count": 4,
      "location_summary": "Little Rock, Arkansas • Miami, Florida • Bellaire, Texas + 1 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Bellaire",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06545097"
    },
    {
      "nct_id": "NCT00552227",
      "title": "Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "ruboxistaurin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Chromaderm, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "35 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2002-09",
      "completion_date": "2005-07",
      "has_results": false,
      "last_update_posted_date": "2016-07-26",
      "last_synced_at": "2026-10-29T23:14:01.062Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00552227"
    },
    {
      "nct_id": "NCT00567086",
      "title": "Study to Assess the Safety, Tolerance and Efficacy of Tezampanel in Patients With Acute Migraine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "TEZAMPANEL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TorreyPines Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 306,
      "start_date": "2006-10",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2007-12-04",
      "last_synced_at": "2026-10-29T23:14:01.062Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00567086"
    },
    {
      "nct_id": "NCT03536754",
      "title": "A Study of CCX140-B in Subjects With FSGS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "FSGS",
        "Focal Segmental Glomerulosclerosis",
        "Glomerulosclerosis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "CCX140-B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 46,
      "start_date": "2018-05-17",
      "completion_date": "2020-02-19",
      "has_results": true,
      "last_update_posted_date": "2025-03-13",
      "last_synced_at": "2026-10-29T23:14:01.062Z",
      "location_count": 9,
      "location_summary": "Phoenix, Arizona • Torrance, California • Shreveport, Louisiana + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03536754"
    },
    {
      "nct_id": "NCT05291286",
      "title": "BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Neuropathy;Peripheral",
        "Chemotherapy-induced Peripheral Neuropathy"
      ],
      "interventions": [
        {
          "name": "BXQ-350",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2022-10-17",
      "completion_date": "2024-12-20",
      "has_results": false,
      "last_update_posted_date": "2025-01-27",
      "last_synced_at": "2026-10-29T23:14:01.062Z",
      "location_count": 3,
      "location_summary": "Cincinnati, Ohio • Columbus, Ohio • Nashville, Tennessee",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05291286"
    },
    {
      "nct_id": "NCT04716231",
      "title": "Atacicept in Subjects With IgA Nephropathy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "IgA Nephropathy",
        "Berger Disease"
      ],
      "interventions": [
        {
          "name": "Atacicept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to match Atacicept",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Vera Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 428,
      "start_date": "2023-06-29",
      "completion_date": "2028-07",
      "has_results": true,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-29T23:14:01.062Z",
      "location_count": 1,
      "location_summary": "Brisbane, California",
      "locations": [
        {
          "city": "Brisbane",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04716231"
    },
    {
      "nct_id": "NCT04770389",
      "title": "Randomized Study of Obicetrapib in Combination With Ezetimibe",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyslipidemias",
        "High Cholesterol",
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Obicetrapib 5mg",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe 10mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NewAmsterdam Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 112,
      "start_date": "2021-02-23",
      "completion_date": "2021-06-30",
      "has_results": true,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-10-29T23:14:01.062Z",
      "location_count": 3,
      "location_summary": "Lincoln, California • Evanston, Illinois • Houston, Texas",
      "locations": [
        {
          "city": "Lincoln",
          "state": "California"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04770389"
    },
    {
      "nct_id": "NCT00605891",
      "title": "Dose Finding Study of CHF 4226 for Treating Patients With COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "carmoterol (CHF 4226)",
          "type": "DRUG"
        },
        {
          "name": "salmeterol",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chiesi Farmaceutici S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 278,
      "start_date": "2006-10",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2017-04-11",
      "last_synced_at": "2026-10-29T23:14:01.062Z",
      "location_count": 24,
      "location_summary": "Jonesboro, Arkansas • Fresno, California • San Diego, California + 19 more",
      "locations": [
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00605891"
    }
  ]
}